Radiosensitization by BRAF inhibitor therapy—mechanism and frequency of toxicity in melanoma patients
Hecht, M. ; Zimmer, L. ; Loquai, C. ; Weishaupt, C. ; Gutzmer, R. ; Schuster, B. ; Gleisner, S. ; Schulze, B. ; Goldinger, S. M. ; Berking, C. ; Forschner, A. ; Clemens, P. ; Grabenbauer, G. ; Müller-Brenne, T. ; Bauch, J. ; Eich, H. T. ; Grabbe, S. ; Schadendorf, D. ; Schuler, G. ; Keikavoussi, P. ; Semrau, S. ; Fietkau, R. ; Distel, L. V. ; Heinzerling, L.
In: Annals of Oncology, 2015, vol. 26, no. 6, p. 1238-1244
Ajouter à la liste personnelle- Summary
- This study shows radiosensitization by BRAF inhibitors in clinical practice and ex vivo by fluorescence in situ hybridization of chromosomal breaks. Nevertheless, radiotherapy with concomitant BRAF inhibitor therapy is feasible with an acceptable increase in toxicity. Vemurafenib is a more potent radiosensitizer than dabrafenib in both the patient study and the ex vivo experiments